Stable overexpression of native and artificial miRNAs for the production of differentially fucosylated antibodies in CHO cells.
CHO
biopharmaceuticals
biosimilar
fucosylation engineering
microRNA
Journal
Engineering in life sciences
ISSN: 1618-0240
Titre abrégé: Eng Life Sci
Pays: Germany
ID NLM: 101193313
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
08
08
2023
revised:
04
03
2024
accepted:
17
03
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
7
6
2024
Statut:
epublish
Résumé
Cell engineering strategies typically rely on energy-consuming overexpression of genes or radical gene-knock out. Both strategies are not particularly convenient for the generation of slightly modulated phenotypes, as needed in biosimilar development of for example differentially fucosylated monoclonal antibodies (mAbs). Recently, transiently transfected small noncoding microRNAs (miRNAs), known to be regulators of entire gene networks, have emerged as potent fucosylation modulators in Chinese hamster ovary (CHO) production cells. Here, we demonstrate the applicability of stable miRNA overexpression in CHO production cells to adjust the fucosylation pattern of mAbs as a model phenotype. For this purpose, we applied a miRNA chaining strategy to achieve adjustability of fucosylation in stable cell pools. In addition, we were able to implement recently developed artificial miRNAs (amiRNAs) based on native miRNA sequences into a stable CHO expression system to even further fine-tune fucosylation regulation. Our results demonstrate the potential of miRNAs as a versatile tool to control mAb fucosylation in CHO production cells without adverse side effects on important process parameters.
Identifiants
pubmed: 38845814
doi: 10.1002/elsc.202300234
pii: ELSC1610
pmc: PMC11151017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2300234Informations de copyright
© 2024 The Authors. Engineering in Life Sciences published by Wiley‐VCH GmbH.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.